L-732138 NEW
| Price | $43 | $73 | $137 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-22 |
Product Details
| Product Name: L-732138 | CAS No.: 148451-96-1 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2025/07/22 |
Product Introduction
Bioactivity
| Name | L-732138 |
| Description | L-732138 is a potent and competitive antagonist of neurokinin-1 (NK-1) receptor(IC50 : 2.3 nM) |
| Cell Research | Cell Line:COLO 858, MEL HO and COLO 679 cells. Concentration:0 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM. Incubation Time:First doubling time[1]. |
| Animal Research | Animal Model:Male Dunkin-Hartley guinea-pigs (350-500 g) injected with lipopolysaccharide (LPS)[3].Dosage:10-4 mol/kg ,10-3 mol/kg and 10-2 mol/kg. Administration:Intravenous injection; for 15 minutes[2] |
| In vitro | L-732,138 against three human melanoma cell lines (COLO 858, MEL HO, COLO 679).?L-732,138 elicits cell growth inhibition in a concentration dependent manner in the melanoma cells studied.?Moreover, L-732,138 blocks SP mitogen stimulation.?The specific antitumor action of L-732,138 occurred through the NK-1 receptor and melanoma cell death was by apoptosis[1]. |
| In vivo | L-732138?Abolished the vagally-induced plasma leakage in tracheobronchial tissues, and dose-dependently inhibited the LPS enhanced vagally-induced plasma exudation in traceobronchial tissues[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.72 mg/mL (9.99 mM), Sonication is recommended. |
| Keywords | vagally-induced | Tachykinin receptor | stimulation | plasma | peralgesia | ntravenously | NK1 | NK receptor | Neurokininreceptor | Neurokinin receptor | Neurokinin Receptor | mitogen | lipopolysaccharide | L-732138 | L732138 | L 732138 | Inhibitor | inhibit | cytotoxicity | apoptotic | Antitumorhy |
| Inhibitors Related | Maropitant citrate | Rolapitant | Ezlopitant | (R)-CJ 11974 | N-Acetyl-L-tryptophan | Netupitant | Aprepitant | Vofopitant dihydrochloride | Befetupitant | Vofopitant | Fosaprepitant dimeglumine | Maropitant |
| Related Compound Libraries | Apoptosis Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP2Y
|
Anhuyan (Hainan) Biotechnology Co., LTD
|
2025-06-10 | |
| $0.00/10kg |
VIP3Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-10-23 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY